Phase II trial of Baker's antifol in metastatic renal cell carcinoma: a Southwest Oncology Group Study.
Fifteen patients with metastatic renal cell carcinoma were treated with Baker's antifol at a dose schedule of 250 mg/m2 iv for 3 days every 3 weeks. One objective response was seen, and toxicity was minimal. No usefulness of Baker's antifol in the treatment of metastatic renal cell carcinoma was demonstrated.